文献速递炎症性肠病

Mongersen(GED-0301)治疗活动性克罗恩病:3期研究结果

Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

这项3期盲法研究将701例活动性克罗恩病患者随机分配至安慰剂或三种口服GED-0301方案,主要终点第12周临床缓解率在GED-0301组为22.8%,安慰剂组为25%(P=0.6210),无显著差异。研究提前终止,第52周临床缓解率各组相似,GED-0301未显示优于安慰剂的疗效。

要点

  • GED-0301第12周临床缓解率22.8% vs 安慰剂25%,无显著差异(P=0.6210)。
  • 第12周内镜应答率安慰剂组18.1%高于GED-0301组10.1%。
  • 不良事件主要为胃肠道反应且与活动性CD相关,2例死亡与治疗无关。

核心结论

  • GED-0301在活动性克罗恩病患者中未显示优于安慰剂的疗效。

研究设计与样本

  • 3期盲法研究,将701例活动性克罗恩病患者按1:1:1:1随机分配至安慰剂或三种每日一次口服GED-0301方案。
  • GED-0301方案包括:160 mg治疗12周后40 mg持续,或40 mg与安慰剂交替每4周,或160 mg与安慰剂交替每4周,持续至第52周。

主要发现

  • 第12周临床缓解(CDAI评分<150)率GED-0301组22.8% vs 安慰剂组25%(P=0.6210)。
  • 第12周内镜应答(CD简单评分较基线下降>50%)率安慰剂组18.1% vs GED-0301组10.1%。
  • 第12周临床应答(CDAI评分下降≥100分)率安慰剂组44.4% vs GED-0301组33.3%。
  • 第52周临床缓解率和临床应答率在各GED-0301组与安慰剂组间相似。
  • 不良事件主要为胃肠道反应且与活动性CD相关,2例死亡(小肠梗阻和肺炎)经研究者判断与治疗无关。

临床怎么用

  • 不推荐将GED-0301用于活动性克罗恩病的治疗。

局限性

  • 研究提前终止,仅5.8%(41/701)患者完成第52周,长期数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The objective was to assess the efficacy and safety of GED-0301, an antisense oligodeoxynucleotide to Smad7, in active Crohn's disease (CD). METHODS: This phase 3, blinded study randomized patients (1:1:1:1) to placebo or 1 of 3 once-daily oral GED-0301 regimens: 160 mg for 12 weeks followed by 40 mg continuously or alternating placebo with 40 or 160 mg every 4 weeks through week 52. RESULTS: In all, 701 patients were randomized and received study medication before premature study termination; 78.6% (551/701) completed week 12, and 5.8% (41/701) completed week 52. The primary endpoint, clinical remission achievement (CD Activity Index score <150) at week 12, was attained in 22.8% of patients on GED-0301 vs 25% on placebo (P = 0.6210). At study termination, proportions of patients achieving clinical remission at week 52 were similar among individual GED-0301 groups and placebo. More placebo vs GED-0301 patients achieved endoscopic response (>50% decrease from baseline Simple Score for CD) at week 12 (18.1% vs 10.1%). Additional endoscopic endpoints were similar between groups at weeks 12 and 52. More placebo vs GED-0301 patients had clinical response (≥100-point decrease in the CD Activity Index score) at week 12 (44.4% vs 33.3%); at week 52, clinical response rates were similar. Adverse events were predominantly gastrointestinal and related to active CD, consistent with lack of clinical and endoscopic response to treatment. Two deaths occurred (GED-0301 total group) due to small intestinal obstruction and pneumonia; neither was suspected by the investigator to be treatment-related. DISCUSSION: GED-0301 did not demonstrate efficacy vs placebo in active CD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Sands BE, Feagan BG, Sandborn WJ, et al. Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. Am J Gastroenterol. 2020. PMID: 31850931. doi:10.14309/ajg.0000000000000493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。